Literature DB >> 1780235

Serum immunoreactive erythropoietin level: a new parameter for monitoring transfusion management of thalassaemia.

M André1, P Bergmann, A Ferster, M Toppet, P Fondu.   

Abstract

Serum immunoreactive erythropoietin (EPO) was measured sequentially in 8 patients with thalassaemia major. The EPO levels were distinctly increased before transfusion; they did not significantly change just after transfusion, but subsequently decreased. Pretransfusion EPO levels were similar to those observed in patients with non renal non inflammatory anaemias of the same severity. Our results show that production of EPO is appropriately increased in thalassaemia major and confirm that stimulation of endogenous erythropoiesis is not completely suppressed by the hypertransfusion regimen commonly used in this disease. As hyperstimulated ineffective erythropoiesis may lead to invalidating complications, we suggest that serum EPO measurements, which are now easily and reliably performed, should be used in monitoring the therapy of thalassaemia major.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1780235

Source DB:  PubMed          Journal:  Nouv Rev Fr Hematol


  2 in total

1.  Low doses of rHuEPO administered to adult patients with thalassemia intermedia.

Authors:  F Dore; E Gaviano; S Bonfigli; S Pardini; P Pistidda; L Guiso; M Longinotti
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

2.  Serum erythropoietin levels in thalassemia intermedia.

Authors:  F Dore; S Bonfigli; E Gaviano; S Pardini; P Cianciulli; G Papa; M Longinotti
Journal:  Ann Hematol       Date:  1993-10       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.